GlassScriptPhysician profile
Lissette E Jimenez
NPI 1932631322
$604.70
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $75.37 · 2021: $385 · 2022: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $184.33 | 2020-2022 | |
| Gilead Sciences, INC. | $87.27 | 2021-2022 | |
| Melinta Therapeutics, LLC | $74.04 | 2021 | |
| Janssen Pharmaceuticals, INC | $67.25 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.75 | 2021 | |
| Merck Sharp & Dohme LLC | $24.93 | 2021 | |
| Abbvie INC. | $17.01 | 2022 | |
| Phadia US INC. | $16.13 | 2021 | |
| Pfizer INC. | $15.36 | 2022 | |
| Penumbra, INC. | $11.93 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lissette Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.